Kala Pharmaceuticals Stock Surges on FDA Update

KALA is up more than 280% today

Deputy Editor
Dec 28, 2022 at 1:18 PM
facebook twitter linkedin

Kala Pharmaceuticals Inc (NASDAQ:KALA) is bucking the broader-market trend this afternoon, up 283.2% lead to trade at $15.02. The breakout comes after the U.S. Food and Drug Administration (FDA) accepted the drugmaker's application to start human trials for its treatment for persistent non-healing corneal defect, KPI-012.

Today's gains mark KALA's best single-session percentage pop of all time, though the shares remain well below their March 16 peak of $97. And while the equity is moving away from its recent all-time low of $3.54, Kala Pharmaceutical stock remains down more than 87% in the last 12 months. 

Call traders are in a frenzy following the news. The stock's normally nonexistent options pits have already seen 535 bullish bets cross the tape, which is 66 times the intraday average volume. Most popular by far is the April 7.50 call, followed by the 7.50 call in the January series, and new positions are being opened at both contracts. 

The success of the trial results could bode well for the security. According to Reuters, the company believes the results could serve as the first of two pivotal trials that could pave the way for a marketing application to the FDA.



Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 



Special Offers from Schaeffer's Trading Partners